Empagliflozin NEW

It can treat adult patients with type 2 diabetes whose blood sugar cannot be well controlled by diet and exercise alone. By inhibiting SGLT - 2 in the proximal renal tubules of the kidneys, it blocks the reabsorption of glucose by the kidneys and increases the excretion of glucose in the urine, thereby reducing blood glucose levels. Notably, this hypoglycemic effect does not depend on the function of pancreatic β - cells and is not affected by insulin resistance, which makes it applicable to many type 2 diabetes patients with different disease conditions.

It can be used in combination with other hypoglycemic drugs to enhance the hypoglycemic effect. For example, when combined with metformin, it can achieve better blood sugar control for patients; and it can also be used in combination with insulin or sulfonylureas. However, attention should be paid to the increased risk of hypoglycemia when combined with the latter two.

Clinical studies have found that for patients with type 2 diabetes who are at high cardiovascular risk, on the basis of standard treatment, adding Empagliflozin can reduce the occurrence of cardiovascular events and reduce the mortality rate of patients. Relevant medical regulatory authorities such as the EMA and FDA have also conducted in - depth analysis on such clinical trial results to further clarify and add its cardioprotective indication.

It serves as an important research reagent in in - vitro and in - vivo pharmaceutical experiments. In cell experiments, it can inhibit the uptake of (14C) - AMG in a dose - dependent manner by targeting hsGLT - 2. In animal experiments, administering it to diabetic rats can significantly reduce their blood sugar levels and improve metabolic syndrome, providing a reliable tool for the research on SGLT - 2 inhibitor - related drugs and the pathological mechanism of diabetes.